Neal Shore, Steven A. Kaplan, Ronald Tutrone, Richard Levin, James Bailen, Alan Hay, Susan Kalota, Mohamed Bidair, Sheldon Freedman, Kenneth Goldberg, Frederick Snoy & Jonathan I. Epstein
Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al.
Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.
Neal D. Shore, Alicia K. Morgans, Charles J. Ryan
Dr. Neal Shore Featured In Grand Strand Magazine
Maha Hussain, M.D., Joaquin Mateo, M.D., Karim Fizazi, M.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Antoine Thiery-Vuillemin, M.D., Przemyslaw Twardowski, M.D., et al., for the PROfound Trial Investigators*
Prostate cancer treatment interview with Dr. Neal Shore featured on WCSC Live 5 News
Click on the video below to watch the interview:
Karim Fizazi, M.D., Neal Shore, M.D., Teuvo L. Tammela, M.D., Ph.D., Albertas Ulys, M.D., Egils Vjaters, M.D., Sergey Polyakov, M.D., Mindaugas Jievaltas, M.D., Murilo Luz, M.D., Boris Alekseev, M.D., Iris Kuss, M.D., Marie-Aude Le Berre, M.Sc., Oana Petrenciuc, M.D., et al., for the ARAMIS Investigators*
‘Coming into their own’: FDA approval of liquid biopsy tests puts early, less invasive cancer detection in broader reach
First patient in treatment in RhoVac’s clinical phase IIb study in the USA
